<SEC-DOCUMENT>0001437749-13-003729.txt : 20130401
<SEC-HEADER>0001437749-13-003729.hdr.sgml : 20130401
<ACCEPTANCE-DATETIME>20130401083948
ACCESSION NUMBER:		0001437749-13-003729
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130401
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130401
DATE AS OF CHANGE:		20130401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO KEY INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001019034
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER COMMUNICATIONS EQUIPMENT [3576]
		IRS NUMBER:				411761861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13463
		FILM NUMBER:		13728971

	BUSINESS ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719
		BUSINESS PHONE:		6516870414

	MAIL ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SAC TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19961115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bkyi20130329_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>bkyi20130329_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA3><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>UNITED STATES</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA4><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA5><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA6><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt">Washington, D.C. 20549</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA7><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA8><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>FORM 8-K</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA9><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>CURRENT REPORT</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA11><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA13><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): April 1, 2013</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA15><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA16><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL39  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA17><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>BIO-key International, Inc.</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA20><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3></TD></TR>
<TR>
<TD style="WIDTH: 33.7%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Delaware</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA22><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</FONT></P></TD>
<TD style="WIDTH: 33.7%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA23><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>1-13463</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA24><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(Commission File Number)</FONT></P></TD>
<TD style="WIDTH: 33.7%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA25><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>41-1741861</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>3349 Highway 138, Building D, Suite B</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA29><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Wall, NJ&nbsp;07719</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(Address of principal executive offices)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(732)&nbsp;359-1100</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(Registrant&#146;s telephone number, including area code)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3></TD></TR>
<TR>
<TD style="WIDTH: 101.1%; VERTICAL-ALIGN: top" colSpan=3>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA34><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2 below):</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt" id=PARA35><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9744;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt">&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt" id=PARA36><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9744;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt">&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt" id=PARA37><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9744;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt">&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; MARGIN: 0pt 0pt 0pt 18pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9744;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"> Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P></TD></TR></TABLE>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA40.1>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK40 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR40 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM40 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR40 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA40.2>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA41><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 2.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; MARGIN: 0pt" id=PARA42><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On April 1, 2013, BIO-key International, Inc. (the &#147;Company&#148;) issued a press release announcing its financial results for its fourth quarter and year ended December 31, 2012 which is included as an exhibit to a Current Report on Form 8-K.&nbsp;A copy of the press release issued by the Company on April 1, 2013 is attached as Exhibit&nbsp;99. </FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER">&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements, Pro Forma Financial Information and Exhibit.</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA47><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release, dated April 1, 2013, issued by </FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">the Company.</FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA80.1>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK80 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR80 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM80 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR80 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA80.2>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>SIGNATURES</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; MARGIN: 0pt" id=PARA51><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER">&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER">&nbsp;</P>
<TABLE  border=0 cellSpacing=0 cellPadding=0 width="100%">

<TR>
<TD vAlign=top width="50%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="38%" colSpan=2><FONT size=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-KEY INTERNATIONAL, INC.</FONT></P></FONT></TD>
<TD vAlign=top width="12%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=top width="50%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="3%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="35%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="12%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: #ffffff solid; TEXT-ALIGN: left" vAlign=top width="50%" align=left><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA55><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Date: April 1, 2013</FONT></P></FONT></TD>
<TD style="BORDER-BOTTOM: #ffffff solid; TEXT-ALIGN: left" vAlign=top width="3%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: </FONT></TD>
<TD style="BORDER-BOTTOM: black 2px solid" vAlign=top width="35%" noWrap align=left><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&nbsp;Cecilia C. Welch</FONT></TD>
<TD style="BORDER-BOTTOM: #ffffff solid" vAlign=top width="12%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=top width="50%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="3%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=bottom width="35%" noWrap align=left><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cecilia C. Welch</FONT></TD>
<TD vAlign=top width="12%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD vAlign=top width="50%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="3%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD>
<TD vAlign=top width="35%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</FONT></TD>
<TD vAlign=top width="12%"><FONT style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&nbsp;</FONT></TD></TR></TABLE>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA81.1>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK81 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR81 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM81 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR81 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA81.2>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>EXHIBIT INDEX</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA64><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB72  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 138pt; VERTICAL-ALIGN: top">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA67><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Exhibit No.</B></FONT></U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><B></B></B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA69><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Description</B></FONT></U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 138pt; VERTICAL-ALIGN: top"></TD>
<TD style="VERTICAL-ALIGN: top"></TD></TR>
<TR>
<TD style="WIDTH: 138pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA73><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">99.1</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA74><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Press Release, dated </FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">April 1, 2013, issued by </FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">the Company.</FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA75><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>bkyi20130329_8kex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>bkyi20130329_8kex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="TEXT-ALIGN: right; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA140><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: right; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Exhibit 99.1</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"  cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 33%" rowSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA149>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA141><IMG style="WIDTH: 144pt; HEIGHT: 108pt" src="bkyi20130329_8kex99-1img001.jpg"></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: bottom" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA150><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 24pt"><B><I>NEWS RELEASE</I></B></FONT></P></TD></TR>
<TR>
<TD>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA153>&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA154>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">BIO-key International, Inc.</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">Jay Meier</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">651-789-6116</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B><I>BIO-key&#174; International Inc.<BR>Reports Profitable Fourth Quarter and Full Fiscal Year 2012</I></B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA22><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Wall, NJ, April 1, 2013</B> &#150; </FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key International, Inc. (OTCBB: BKYI), a global leader in fingerprint biometric identification solutions, advanced mobile credentialing and identity verification technologies, today reported financial results for the fourth quarter and full year ended December 31, 2012.&nbsp; </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA23><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA24><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total revenue for the three months ended December 31, 2012 was $1,482,835 compared to $545,451 for the same period last year, an increase of 172%. This increase is directly related to o</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">rders for new business including expanded services and technologies for several hospitals, reaching agreements with two blood centers to install BIO-key&#146;s TruDonor ID and sales developed through growing OEM relationships. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA25><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Gross profit and gross profit margin for the three months ended December 31, 2012 were $1,333,583 and 90%, respectively, as compared to $353,325 and 65%, respectively, for the three months ending December 31, 2011. The increase in gross profit percentage was driven primarily by increased core license revenues and decreased third party hardware sales and associated higher costs of goods sold.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Operating expenses for the three months ended December 31, 2012 were approximately $842,000, a decrease of 36% as compared to operating expenses of approximately $1,324,000 for the same period in 2011. This decrease was driven by reversal of bad debt expense and reduced R&amp;D consulting expenses, offset by increased commission related to increased revenue, and the legal and settlement fees related to the alleged patent infringement suit.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA29><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Operating income for the period ended December 31, 2012 was $491,967 compared to an operating loss of ($970,590) for the same period in 2011. Total net income for the fourth quarter of 2012 was $485,797 compared to a net loss of ($1,003,286) for the comparable 2011 period. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Michael DePasquale, BIO-key&#146;s Chief Executive Officer stated &#147;The Fourth Quarter of 2012 was strong and representative of the model we are building. We grew revenue from a diversified customer base, while keeping expenses in line, driving profitability in both the Quarter and Fiscal Year 2012. It was a milestone for us and we are proud of what we accomplished in Fiscal 2012.&#148;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK146 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR146 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM146 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR146 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA146.2>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA37><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>Full Year Comparisons </U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA39><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total revenue for the year ended December 31, 2012 was approximately $3.8 million compared to approximately $3.5 million for the year ended December 31, 2011, an increase of 9%. Driving this increase was a higher core license sales, offset with lower third party hardware sales which has a higher cost of goods sold.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA40><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA41><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Gross profit and gross profit margins for the year ended December 31, 2012 were approximately $3.3 million and 85% respectively, as compared to approximately $2.7 million and 77% respectively, for the year ended December 31, 2011. The increase in gross profit margin is directly attributable to higher licensing fees as a percentage of net sales for the comparable period. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA42><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Operating expenses for the year ended December 31, 2012 were approximately $3.2 million, a decrease of 22 % as compared to operating expenses of $4.2 million for the same period in 2011. Adjusting for bad debt expense in both years and the patent infringement legal and settlement charges in 2012, the normalized decrease is 10%.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA45><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company reported an operating profit of $27,886 compared to an operating loss of approximately ($1.45 million) for the periods ended December 31, 2012 and December 31, 2011, respectively. BIO-key&#146;s net income for the year ended December 31, 2012 was $3,267 compared to net loss of approximately ($1.9 million) for the same period in 2011. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA46><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA47><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>Highlights for the fourth quarter and Full Fiscal Year included the following:</U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA49><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA50><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>Q4 2012 Highlights</U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA51><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA138>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB53  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA54><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA55><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Received orders in excess of $1 million from healthcare and blood center customers in the fourth quarter.</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 36pt" id=PARA56><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA137>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB58  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA59><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA60><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Completed the installation and delivery of our technology for a large scale international biometric identification project.</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA61><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA136>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB63  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA64><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA65><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Launched integration efforts into Allscripts Professional EHR. Pro EHR provides small to midsize healthcare organizations with electronic health records management solutions and has the largest marketshare of the Allscripts EHR solution offerings.</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA66><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA135>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB68  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA69><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA70><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Initiated relationship discussions with InterDigital Communications Inc. leading to completion of R&amp;D collaboration agreement as well as investment in BIO-key in the first quarter of 2013.</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA71><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK147 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR147 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM147 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR147 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA147.2>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA75><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>2012 Full Year Highlights</U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA76><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA134>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB78  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA79><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA80><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Awarded contract to provide the Provincial Government of British Columbia Department of Corrections with fingerprint biometric authentication solutions for inmates seeking to access personnel records. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 18pt" id=PARA81><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA133>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB83  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA84><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA85><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">IBM produced an IBM Redguide; </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#147;<I>BIO-key Biometric Service Provider for IBM Security&#148;<B> Redguide</B></I> is the go-to resource for IBM sales and support technicians seeking innovative customer solutions. IBM distributed the Redguide to thousands of IBMers and hosts the guide on the IBM website. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA87><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA132>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB89  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA90><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA91><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">IBM reseller Dancom installed BIO-key technology which is currently integrated into the IBM TAM and ISAM ESSO platforms to provide fingerprint biometric authentication solutions for Aeon Credit Services. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA92><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA131>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB94  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA95><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA96><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key&#146;s biometric algorithm achieved top scores for accuracy during the most recent evaluation conducted within the National Institute of Standards and Technologies (NIST) PFT II testing suite. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA97><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA130>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB99  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA100><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA101><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key was awarded three new blood center contracts; expanding our national footprint to include six blood centers and over three million blood donor identification licenses. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA102><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA129>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB104  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA105><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA106><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Purchase orders for continued rollouts at LexisNexis, Identimetrics, Solfed, Team Praxis, Union Pacific, Davlong, Medflow, Robinson Memorial Hospital, Muskingum Valley Health Center, Children&#146;s Medical Center of Dayton, Nationwide Children&#146;s Hospital, McKesson, NCR and AT&amp;T.</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 36pt" id=PARA107><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA128>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB109  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA110><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA111><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key was issued US Patent No 8,214,652 for the Company&#146;s &#147;Biometric Identification Network Security,&#148; an expanded method of network and related network authentication security systems utilizing hardware based support for encryption and key management for authentication purposes. </FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA112><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA113><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DePasquale continued, &#147;We believe that the marketplace for biometrics, including Mobile Credentialing and Payments, is finally emerging and that we have strategically positioned the company to capitalize on this opportunity.&nbsp; In line with our objectives we&#146;ve hired strategic development personnel, as well as additional technical support staff to prepare for the next phase of growth.&nbsp;&nbsp; Although the landscape is improving we recognize that the growth of our company and the growth of the entire biometric industry will be choppy and unpredictable for the foreseeable future. In line with this for 2013 we have set three primary goals; First, we remain committed to growing the Company by developing new partnerships in the Mobility, Healthcare and Services markets as we are starting to witness the benefit of our leveraged sales model.&nbsp; Also, the Company will continue to forward existing strategic relationships and provide ongoing support to our customers.&nbsp; Second, as much as possible, we intend to smooth the volatility of our business to enhance shareholder value, within an emerging and rapidly changing landscape.&nbsp;&nbsp; Our third objective, which we have already taken the first step towards delivering, is to ultimately drive shareholder equity through positive cash flow and more consistent bottom line profitability.&#148;&nbsp; </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA114><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK148 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR148 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM148 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR148 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA148.2>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA115><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><U>Conference Call Details<BR></U></B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA117><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key has scheduled a call for Monday April 1, 2013 at 10:00 a.m. Eastern Time to discuss 2012 fourth quarter and year end results. To access the conference call live, dial 800-860-2442 (international: 412-858-4600) and ask for the BIO-key call at least 10 minutes prior to the start time.&nbsp;&nbsp;The conference call will also be broadcast live over the Internet by logging onto <U>www.bio-key.com</U></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">. A streaming audio replay of the conference call will be available through April 29, 2013 and may be accessed by dialing 877-344-7529 (international: 412-317-0088) and using the pass code 10026640#. </FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA120><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About BIO-key</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA121><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">BIO-key International, Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers.&nbsp;BIO-key&#146;s award winning, high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications. Our solutions are used in local embedded OEM products as well as some of the world&#146;s largest identification deployments to improve security, guarantee identity, and help reduce identity theft.&nbsp;&nbsp;BIO-key&#146;s technology is offered directly or by market leading partners around the world. (<U>http://www.bio-key.com</U></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">)</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA122><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA123><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA124><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>BIO-key Safe Harbor Statement</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA125><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Certain statements contained in this press release may be construed as &#147;forward-looking statements&#148; as defined in the Private Securities Litigation Reform Act of 1995 (the &#147;Act&#148;).&nbsp; The words &#147;estimate,&#148; &#147;project,&#148; &#147;intends,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;believes&#148; and similar expressions are intended to identify forward-looking statements.&nbsp; Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the &#147;safe-harbor&#148; provisions of the Act.&nbsp; These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements.&nbsp; These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, our ability to attract and retain key personnel.&nbsp; For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012 and its other filings with the Securities and Exchange Commission.&nbsp; Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.&nbsp; The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events. </FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="BEFORE"><BR></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA126><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#169; Copyright 2013 by BIO-key International, Inc.</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>bkyi20130329_8kex99-1img001.jpg
<TEXT>
begin 644 bkyi20130329_8kex99-1img001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``4$!`0$`P4$!`0&!04&"`T("`<'
M"!`+#`D-$Q`4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!#`04&!@@'"`\("`\@%1(5("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("#_P``1"`"0`,`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#[+S29HHH`
M,T9HJK?W]EIEA+?ZC=PVEK"NZ2:9PB(/4DT-C2;=D6LTV25(T9W9411DLQP`
M/<U\^>,_VDM.LWDLO!-A_:4PROV^Z!2$>ZIPS_4[1]:\"\2>.O%WBZ5F\0:]
M<W<9.1;JWEPK]$7`_/->;6S"E#2.K/I,'P[BL0N:I[B\]_N_SL?8VN_&'X=^
M'G:*\\2V]Q.O6&SS<-]/DR!^)KSW4_VH/#T+%=(\,ZC>@='GD2`'_P!"/Z5\
ML(F76.-"68X5%&23Z`#K7>:!\'_B+XB19;/PY+:V[#(FOV%NI'J`WS'\JX?K
MV(J.U-?A<^@60Y=A8\V)G?U=OZ^\]#NOVH?$+L?L7A33XE[>=</(?T"U3_X:
M=\9_]`#1ORE_^*J_I?[+^KR@-K7BNTMN.4M+=I3^;%?Y5U-K^S#X5C&;SQ%J
M]P?]@1Q_^RFK4,=+6]ON.>5;(*>BC?Y29QT'[4'BE6'VKPQI<J]_+ED0_KFN
MDT[]J/2W*KJWA*\@'=[:X24?DP6MW_AFGX?[,?;=:W8Z_:4_^(K+N_V7_#3C
M_0O$VJVY_P"FB1R#^0K10QT=FF<TJV0U-'!K[_\`,[31/CG\-M;=8AKHTZ9N
M!'J$9AY_WC\OZUZ);7EM>6Z7-I<17$+\K)$X=6^A'!KY<U;]F'Q!`&;1O$MA
M>@=$N86A8_B-PKC'\)_&#X8W#7UE::G81)RT^GOY\##_`&E7(Q_O+6BQ5>G_
M`!H:=T<\LJR_$?[GB->TOZ3_``9]N9HS7S5X*_:5+/'8^.K``?=_M&R4X'O)
M%_5?RKZ'TK5M-UO3(M2TF^AOK.892:%PRM_]?VZUW4<13K+W&>%C,OQ&#E:M
M&WGT?S+V:,T45N<`9HS110`9HS110`9I0<TE`H`*0D#K2FO-OBM\4++X>Z(L
M=NJ76NW:G[+;$\*.AE?'\(].YX]2(G.-.+E+9&U"A4Q%14J2NV7OB'\3O#_P
M]TT/?.;O4IE)MM/B8>9)_M,?X5S_`!'\,FOC_P`:_$#Q-X\U'[1KEX1;(V8+
M&$E8(?HO\1_VCD_2L'5-4U'6]5N-6U:\DO+ZY;?+-(>6/]`.P'`J70M"U;Q+
MKEOHNB63WE]<'"1KP`.[,>BJ.Y-?-XC%5,1+ECMV/T[+LHP^70]K4LYK=O9>
MG;UW,\!F9552S,0JJ!DD]@!W->U>!/V>_$'B&.+4?%,SZ%I[_,L&T&ZD'T/$
M8^N3[5[/\-/@UH7@:&+4;T1ZIX@(RUVZ_)`>ZQ`]/][J?;I7J0&*[L-ER2YJ
MWW'@YEQ+*3=/!Z+^;_+^ON.3\*_#KP?X,B4:#HD,5P!AKJ4>9,WU=N?P&!76
MT45Z\8J*M%6/C:E2=67/4;;\PHHI,U1F+16'XA\6^'/"EF+OQ#K%MI\;?=$K
M_._^ZH^9OP%>/:W^T]X9LW:/1-"OM2`X$LS+;H?IG+?H*PJ8BE3^.5CNPV7X
MK%:T8-KOT^_8]\R*.W%?-5O^T#\0-5(?1?AM]IC/0HD\N?Q50*U8?CCX]LL/
MKWPDU)8A]YX%F7'X,A'ZUDL92??[F=DLEQD=&E?MS1O^9Z)XP^$O@KQFCR:A
MI26M\PXOK/$4H/OCA_\`@0->%WGA'XE_`S5)-=\-W1UC0=VZX"*2C+_TVB'*
MG'\:]/4=*]=\.?'GP#KMREC>74^@W[$#R-33RQGTW\K^9%>H!HYX@R,KHZY!
M!!#`_P`Q4RI4JWOTW9]T7#%XS`_N,1&\']F6WR?3Y'&?#WXDZ%\0M&-WIS_9
M[V$#[58R,#)"3W']Y3V8?H>*[;->$>//A3J&@:P/B%\*\V.KVI,L^FPCY+A?
MXMB].>Z=#VP>OHWPZ\>:=\0/"L>K6BB"[B/E7EH3\UO*.H^AZ@^GN#6E*I)/
MV=7XOS.7%8:GR?6,*[P>Z>\7V?EV9V5%%%=1Y@4444`%`HH%`&!XP\4Z=X,\
M*7WB'4F_=6R_)&#AII#PJ#W)X_7M7P;XB\0:IXI\17FO:Q-YMY=ON;'W8U_A
M1?15'`KUK]HKQH^L^,X_"EI+FQT;YI@#P]PPYS_NJ0/J6KQ&OF\?B'4G[-;+
M\S],X>RY8>A]8FO>G^"Z??O]Q9T_3[W5M4M=+TVV>YO+J010Q)U=CT'_`-?L
M*^W/AA\-=-^'OAX0A4N-8NE#7MYCEC_<7T0=AWZFO-?V=_`T%AI$WQ!U=$26
MX5HK$RX`BA'#R9/3<01GT'O7I^J?&+X5Z-.;?4?B!H<<J\%$O%D(^H7.*[\!
MAE"/M9;O8\'B'-'6J/"TG[L=_-_Y+\SN@,4M<5H/Q8^&OB>]6RT+QOI%Y=/P
MD`N561_8*V"?PKL+BYM[2VENKNXCM[>%2\DLK!511U))X`]Z]4^1):*Y?_A8
MOP^QG_A.O#W_`(,X?_BJV-*UO1==MFN=$U>RU2!&V-)9W"3*K>A*D@'VH`OD
MXKPWXO?&T>%9Y?#/A5HY];48N+I@&CL\CH!T:3VZ#OGI7M\[QQP/)+*L2*I+
M.Q`"CUR>E?&:>#_A[HOC^2;QS\6?#=WI2SM,\<-YYEQ=$L3MD"YV9/WCDY[8
MSQR8EUK*-);]>Q[&51P:J2J8QZ15TN[_`*Z#O!/PL\7_`!4U!O$6N:C/;Z=*
MV7U*[)DEN/41*>H]^%';-?2?A7X2^!/"<:-8Z%#<W:CF[O0)I2?4$\+_`,!`
MK5\+^,O!'B6V2#PEXCTG4HX4"K!97",8U`X&P'*@#VKIJ5'"0I:[ON/'9OB,
M4^5/EATBM%_P1%554*HP!P`.U+1178>,8FO>$O#/B:V:WU_0[/4488S-$"P^
MC=1^!KSX>%/$OPO8W_@>>ZUSPVIW7/AVYDWRPKW:U<]Q_</7ZUZ/KOB/0/#&
MG'4?$6M66DV@./-NYUB4GT&3R?85>M+NUU"Q@OK&YCN;6X198IHF#)(A&0RD
M<$$'K64J49.ZT?<ZJ6)J4UR/6/9[?\#U6I2T/6]-\1Z);:SI%R+BSN5W(X&"
M.Q5AU#`Y!!Y!%>3^--*E^&?CJ+XHZ#"RZ/=NMOXALXE^78QP+@`=P3D^_P#O
M&NVCL!X6\=_:+-1'I'B.0K<0CA8;T+E95';S%4JW^TJGJ3767]E:ZEIMSI]]
M`L]K<QM%+&PR'5A@C\C4RBZD;/=?F:TZJP]2\=826J[I[KU71]TF2P317-O'
M<02K+%*@='4Y#*1D$>V*EKSOX5R76F:5JG@?49FENO#%T;2*1^LMJPWV[G_@
M!V_\`KT.M(2YHIG-6I^RJ."=UT\UT?S0M%%%68A0**!0!^<FHWUQJ>K7NI7;
MF2XNYWGE8]V9B3^IJQH&BW/B/Q)IN@V8)FOYU@!`^Z"?F;\%R?PKZ5\2?LTZ
M-J.KSWN@Z_-I,4[ES:R0"9(R3DA#D$#T!SBNQ^''P<T#X?3/J*W$FJ:PZ&/[
M7,@41J>JQJ,[<]SDDU\[#+ZKJ>_MW/TJMQ'A(X>]"_-;16V?F]M/(^>OVOO"
M_B+1M`\.W]AK[1^#[=(]+BT="4"2A7;S"!P^57&3R,>YKS7]F_X+:!\7-4UV
M7Q)?WD%CI"0XALV5'E:0OC+$'``0]!DYZU]`_MI#_BS&CGTUJ/\`]$RUY9^R
M=XX\+?#_`$#QQKGB[5X],L7ELH(W96=I'(G.U54$DX!/`KZ)*VB/S9MMW9E_
MM"_L[:7\+-!LO%GA34[RXTR6Y%K/;WC*TD+L"4974#*G:1@C(..3GCTO]FSQ
M;/\`%_X:>)OA7X]FGU2WM((UCG:4B5[=R1L+]249003V..@KA/VD?V@O#GQ)
M\.V7@WP7'=3V2W2W5S>S1&,2,H8(B*?FQ\V22!T%>M?LF_"?6_`_AW5/%/B:
MSDL-0UL1QP6<HVR10+D[G'\)8GH>0%'K0(^,OBEX9T[P;\5_$?A?27F>QTZ[
M:&$SL&?;@$9(`SU]*_0#X7^#O`_P4^#\WB:&>XAM[K3X=2U.ZN)=Y8B+=A5&
M`.68``9)(&37PU\?O^3AO&O_`&$&_P#017TE^TQXBGTO]F#P1H-NY0:S':";
M!^]'%`KD?]]%#^%`'A'COXG_`!!^/WQ`M]!TP7$=C=W'D:=HD$F(P.S2=F;'
M+,>`,XP*]Y\._L3^'$T>,^*O%NHS:DZ9D&G*D<,;>@WJQ;'J<9]!7#?L4^'X
M+[XB^(/$4\0=]+L5AA)'W7F8Y(]]J,/^!&ON^@#\Y_C#\`/$GP6DM_%OA_6Y
M[_15F55OH08;BRD/W=^T]">`XQSP0,C/T)^S-\>+SXA6LO@[Q=.LGB.QA\V"
MZP%-]",`[A_ST7(SCJ#GJ#7MGQ"\/6_BKX:>(_#UR@=+ZPEC7/9]I*-]0P4_
MA7YC?"CQ%<^%/C#X6UNVD*&#48DDP<;HW;9(OXJS"@#]8:***`/S6_:9\(:Y
MX1^+#+K?BJY\1_VI";^WEN<AH(VD=1%@D@`;?X<#'85]S?`\D_`+P1G_`*!,
M'_H-?)W[;'_)6/#W_8&7_P!'RU[#HOQN\+_"'X#?#6/Q#IVJ7CZCI$;1?8H5
M95"J,Y9F49Y'`R:`/H74]/74K18&?RRDL<R.!DJR.&!'Y8_&KIZ<5X;\/_VG
M?!/Q%\:V?A/1]$UV"\NPY22>WC,:[5+'<5<E1@'G'7%=;\3?C-X(^%-G$WB.
M\DFO[A2UOIUHH>>4?WL$@*N>,L1[9Q1;J.[M8U+BV&G?%ZQU!.$UG3);68#O
M)`X>,GWVR2#\*[$5\BG]LGP5J&NZ;<:AX+UFWALIFD2:*XB=AN1D.4.,C#$X
M#=A7H?B/]JGX9>'],TC4;8:GK=MJD32(]C`N(2IP8Y-[+M<'^'TP>A&9BK-E
MSGS*/=*W]?(]XHKY\\*?M9_#_P`6^+]+\,V.AZ_#=:G<+;1/);QLJLQP"VUR
M0,]3C@<]JV?B3^TAX,^&'C!O"^MZ1K5U>)"DS/:P)Y>&&0`7==WO@8[=0:HS
M/:J!7C7A#]HGPAXV\/ZCJND:5J\1L95A,-U"J>865FR'#%<*%);G(R."6`/H
MOACQ3:^);>5HK>2VGAP7B<A@5)8!E8=1E7'8@JP(!%`'08&>E%%%`'S/^VD/
M^+*Z2?36HO\`T3-7E7[*/@/PK\0_#/C?1?%VE)J-DD]E-&I=D:-P)AN5E((.
M"1UYKOOVTO$FAGP%I'A1=3A;6O[1CO6LE.9%A\N5=[#L,D`9ZUSO[#U[;)=^
M-=/>XC6YE6TECB+`,ZKYH8@=P,C/U%`%?X__`+,WAGP=X#N/&_@1KJVCTXJ;
MRQGE,JF-F"[T8_,""1D$G(STQS)^R5\8M?N_%'_"M/$6H2ZA9W$#RZ;+<.7D
M@=!N:+<>2A4$@'H5XZU[#^U#XVT7PY\$M8T.YNHFU;7(Q:VMH&!=@6!=R.H4
M*#SZD#O7R]^R-X<OM7^/%KK,,+FST6VFGN)0/E4NC1HN?4EB<>BGTH`XKX_?
M\G#>-?\`L(-_Z"*]Y_:ILII/@1\+=0528H(DA8^A>V0C_P!%FO!?C\0?VA?&
MI!!_XF#?^@BONCQGX`_X67^S%8^&K<J+\Z5:7-B['`$Z1*5&>P897/HU`'AO
M[#U]$NK>-=-8@2R0VLZCN0K2*?U9?SK[5K\N_@_XZO/@U\9(-2UFSN(8(V?3
M]5M"I$BQD@-\I_B5E5L=]N.]?I7H'BGPYXHTB+5_#VMV>I64J[A+!*"![,.J
MGU!P10!9UN\AT[P[J>H7#!8;6UEF<GLJH2?T%?DKX2M)M3\>Z#96ZEI;K48(
MD`]6E4#^=?:_[3OQRT#2_`^H>`/#.J0ZAK>J)]GNVMG#K9PG[X9AQO8?+MZ@
M$DXXSY+^R3\+KSQ%X_7Q_J5HRZ+H3$VSNORSW1&%"^H0'<3V.V@#VGQQ^UQX
M>\%^/-9\*/X0U"^?2YS;O<+<)&'<?>PI!P`>_>N;_P"&X-`_Z$#4/_`Y/_B:
M^@=9^$GPS\0ZQ<:QK?@C2;[4+DAIKB6`%Y"!C)/<X`YK/_X45\'_`/HG>B_^
M`XH`^/\`]KG6;?Q%XR\%:]:1O';ZEX;@NXTD'S*LDDC`'W`-9-[\0-0^*GA_
MX<?`[0[F'2=+ABMK6ZNKS"B:Y`QG_<7)"C@LQ^E=%^V?!!:?%+PW:6L*000:
M%'''&B[511-*``!T``Q7'?$#X.W'A_X1^"_BCX=CE;3M1T^`ZB`Q+6MR1Q(#
MV1S^3?4"@#[\\#^!/#'PQ\%Q:-H5FD,%K$6GN64>;<,!EI';N3CIT'0<"OSK
MTJ6]^-O[1UE_;US(ZZ]J@\[YO]7;`D[%]`L:X'TK[`_9V^,D/Q2\$S>$_$=T
M/^$HT^W,4S,?FO8"-HF'JPR`WO@]^/B2RTQ?`WQ@;0?%,UWI\-E>2Z??3VQV
MRQ1.&B>1/7Y&+#U'UH`^C_VD?B)\(O\`A`/^%9^$-,T_4=3MY(U@FL(E$.F[
M&&0KC[S$`J0N1R<G(Q3?@#\"_$FJ?"[QG9>-;!]-TOQ':QII]O=)^]29=Q2Y
MV'E,$KCH6&>V,^P?"SX$_"KX>:5!XJMKBW\07.SSX]<O71HHUZAHQG8@Q_%R
M?>NJ\&?&KP)X_P#'&J>$?"]]/>W6FPF=KD1?Z/,H8*QC?/."P&2`#GC(H`^)
M_P!GCQ+-\,?VAXM&\01+;)>RR:+>"0#,$I?"G)Z8D4`GT8U[!^UMJDWBKQGX
M+^$NAQQRZE=3K<2G:"R-(WEQ+GJ!CS&/M@UPG[7_`(";PY\2[/QQI\1BL]?3
M]ZR<>7=1@`GCIN7:WU#&M_\`9IM=8^)OQKUOXO>,)DGDTBV2-9V7:GGM'Y:D
M9X&V)6)]V!H`^H3\,M%@\`Z1X2TPI90Z5"L43^4&64;0L@E3C>'ZMR#GG-;'
MA7PM'X;AFW70N)I56-1''Y<4$2EBD4:9)"@NW4D\]<``>7:]^TIX5TW5)+/2
M=)O=:BB;:;J-UBC<_P"QNY8>^!FNW^'WQ3\-_$-9XM,\ZTU"W4/+9W(`<+G&
MY2"0RYXR.G>N>&)I3ER1EJ>A5RW%TJ?MJE-J/?\`S['>T445T'GGCWQ9_9[\
M&_%B^36+^XNM*UN.,0B]M2")$&<!T;AL9.",'WKP6Y_8H\3V=YYVA?$*R)4_
M(\MM)`X_%2U?;=>7_M!7]_I?[/GBW4-,O;BQO(8(C'/;R&.1#YT8.&7!'!(_
M&@#P'2OV*M4NM0%SXN^(2R(?OBSMVDD;VWR'C\C7T-9_![PWH/PGU/X?>#;B
MZ\.QZA$5?4K=MUTTAQ^\9N"QXQ@8&"0,5Y)X^\9^,/"?QZTG7M+NKN]T+1_"
MUM?ZUI@E9EEMGG:.694Z%TRK9ZX7KC-=/\-;&'XH>#_&L=[XHUF33QXPO);*
M\T[4I(9/(`4QHK@Y$>'SM'%`'F\O[$*S3/--\3)I)'.YG?3,LQ/4DF7DU[M\
M'/A1/\)_#U]I,WBZ^\0I<RJ\8N$\N.V501MC3<V,YYY[#CBO+OA!I-T_[/.M
M_$&Z\4>(KW6I=,U6#_2]5EEBCV-($=48X5P(U^8<]?6J?P8L;_4V\&ZMJ&B_
M$V2::**XDU.ZUHR:=*VS=O,9D),;'H".XH`]/^*?[/W@7XIR'4K^&72]<"A1
MJ=D`'<#H)%/$@`[G![9Q7SW<_L3^+(+IUTKQ]IKVS<%I8)8G(]PNX'\ZL>+/
M$<=KXN^)EUKFH?$,2VNM/9:7=:-J+PV%I(R#RDD+.%3YR#R,8-=M\1KOXM:5
MH/P;M+'5GD\:8N)KN**?]WJ$D-NLIBDV_+)N52OH2V1US0!E^#_V*]#L;Z*Z
M\:>*IM7B1MQL[&'[.C^S.26(^@4^]?5&D:1I>@Z/:Z/HUA#8:?:((X;>!`J(
MH[`?KGN>:\2^%/Q$M?&OQ6\;>(K;59AH?]C:;<K;33$I8OLD\Y2O16#*0V!S
MC->?_#/XMS7?QMLM?U'QG%>Z5XZN;NSBT4W>]M(,;@6A:/=\AD4$=!DMDT`?
M7=)VS7S1K?P]A7]HO1?"">,_&2:7J>D76HS(NO3@B59`%VG/"@$\5J:IXIUC
MPG\5_BM<VMW=7D&@^$K>[M+2>9GC6148[MI.,D@%CU-`'*^*_P!D"\\6>*+[
M7=1^*E]<O<RNZ&\LO.>-2Q(3=Y@X&>P`]A7IWPP^",?@/P3K?A'7_%%SXMTC
M55$7V.ZBV0P1[2&5%+-@MNR<$?=&!GFO-=5T#7O#7[/]I\:;/XD>(+CQ9':6
MVKS/<7QDLKGS2A:W,'W`F'V@#N!4WCCQ[XN\._M`6/BNPENI?#NG>&K34-:T
M@2,RBVEF9))5CZ%XR5;/7"]<9H`S8?V,?[,\0?VIX>^*%_I7EREX'BL\30KV
M`D61<G'&<#/I7IOQ0_9U\*?$VRL[F]OKFQ\1VMNEO_;$:*SW(50`9DX#GOD8
M(Z9QQ6/X"^(L>C?!OXF>/+[5I-5L]/\`$.IR6,DLQD62/*>1&A)X4EE``X&Z
ML7]G+QM>?\)3J?@C7/&T7BJZU"P@UZWN4N_M'D2.H%Q;9R<%&VX7CC)QS0!P
M]O\`L6>)=RV-U\2H%TO=DI%:R'//787"Y_&OI#X6_"#PC\)M%EL_#T,DU[=8
M^UZA<D&:?'0<<*HYPH_')YK)^!&J:GJOACQ7+JFH7-])!XIU&")KB4R%(U<!
M4!/11V'05ZK,[I`[QQ^8ZJ2J9QN..!GM0!\N_MF>+]$L_AYIW@J6*.YUC4;E
M;R/)YM8H\@R?5B2@]1N]*S&L#\)?V2M$\+J?L^N^*6^TW@'#A7`=P?H@CC/U
M-<78_!_XL_$7X_Q^+OBGX<DTO1Q=_:[Z6>>,PQ6\7*P)ACE<`+]"2>]'Q4\;
MGQWX]N=3@<_V9;#[+8J>/W0/+X]6.3],#M7!CJWLZ5ENSZ#(<"\5BE)KW8:O
M]$</TX%>U?LUZ7=77Q-N]4C4BVL;%UE?'!:1@%7Z_*Q_"O%"0H))X%?;'P/\
M'2>$?AO;F\A\O4M4;[;<`CE-P&Q#]%Q^)->/@*3G63Z+4^TX@Q:H8.4.L]%^
MOX'IU%%%?3GY6%<_XT\):9XZ\%ZEX3UF2XCL-114E:W8+(`'##!(('*CM704
M4`<G'X`T%?&TGBR3SY[R31AH3PRL&A>V#[^5QRQ)P3G&.U5O`OP_\/?"WPQ?
MZ1X:2\:QEN9;\Q2N)75F4`HF`.,*``<GWKM:0@&@#RKX7Z=X!U'X/WGA'PA?
MW\VC-]JM;A;LA;J$S%BX88&T_.<''YX-/\-_!BS\*SZ7_9GQ"\;-9:8R&'3I
M=4#6Q1>D;($&4[8]*Y?XC>&=>^'OBN3XJ>`8]T4G.LZ:`2DJYR9-H['OCE3\
MPZFO2_`GQ!\/^/M&%]H]QLN(P/M%G(1YMNWN.Z^C#@_I7-3K>][.>DOS]#T<
M1A$J:Q%#6F_OB^S_`$?4X;Q#;?#CP5=>)]$\666KC2_'%PUS?7MQ#YEF)&4*
M45U&8R,`C(R#@@\5T'A[P%X0NK'P1=Z9XDO-;B\(>:=-N#=QS%EDC\O;(57Y
M@JX`Z$8'6O0;RSM-0LY+.^MHKJVE&UX9D#HX]"#P:\DUC]G[PQ-=M?\`A35=
M1\)WC'/^@3$Q9_W<@C\&%5-U8N\5=?<11CA:D5&HW"7?=/Y;K\367X)^#K:?
MQO+ILNH:8?&D8BU%;655"#+;C$"IV[M[9SG[QQBK&L?!?P#J_A"Q\-QZ2FEI
MI[0/;7VGQQQ7430XV-YFTDGCDGKFN"G^%GQMM/W>E_%E[B$<+Y\LJ-C\F_G6
M3=?!GXS:R#'K/Q$22(\$-?7#`_\``0H%8O$5%_R[?X'9'+\,]7B8V])?E8]`
M\::U\-_"_CRP\=:[K\DFO:;82:?#8VLBR-(CL&8F,#(;(ZD@5PNF?%#X;:A\
M1=6UZQ\.>)M4UCQ%9QZ;/8""*6.2),@`(&SR"<Y./I5C0_V7]-AD6;Q%XFN+
MOG+Q64(A#?5V+']!7M'ACP3X7\'6AM_#NCP66X8>4#=+)_O.<L?SI1>)F[NT
M5][-*JRNA#E@Y5)=_A7^9YSIW[/WA%K>QAN]4\3R>'8)%NXO"U[J.^Q@DSN"
ME`"2%/\`#N(SGK7H#^!=#E\>7OC&=99KR^TH:--;R$&!K<.7QMQU))!YQCM7
M3@8X%+7<>">4V7P%\$:?X$B\$6\VI?V$FL#67MGG5A,XQB)R5YB^5?EZ\=:Z
M&]^&'A*X\6:!XHL;%='U+0I9'@?38XX!,LB[724!?G4C\1SS7:T4`>2VOP+T
MO3=0O;K1O'OC328KV^DU":TLM46*`RR-N8[0G0]/H*]9R!UIDLT4$#SSR)%%
M&I9W=@JJ!U))Z"OF?XK_`!Y%Y'/X<\"7+"%LQW&JKP6'=8?;_;_+UK"M7A1C
MS3._!8&MC:GLZ2]7T7J/^/'Q8CN%N/`GANY#IG9J=U&W!_Z8*1_X\?P]:^<^
ME`&.E=M\.?ASJ_Q#U[[+;![;2[=@;R^*_+&/[B^KGL.W4U\S4G4Q-3;5GZCA
MZ&'RK"V;LEJWW?\`6R.E^!_PW?QCXG77-3MR="TN0,VX<7,PY6,>H'!;\!WK
M[*48K,T+1-,\.:':Z+H]JMM96B;(T7]23W).23W)K3%?1X;#JA#EZ]3\TS3,
M)X^NZCTBM$O+_-A11174>4%%%%`!1110`UE5E*L`01@@C.:^>?B!\&]7T/6C
MXW^%4LME>QL9)=/MVVGGJ8NQ![QG@]O2OHBDP#VK&K1C55I'9A,95PD^:GL]
MT]FNS1\]>"?VC+1F&D_$"Q;3;R,^6]]#&?+R./WD?WHSZXR/85[QIFK:9K-B
ME]I-_;WUK(,K+;R!U/XBN,\=_"3PGX\1KB^MS8ZKC"ZA:@+)[!QT<?7GT(KY
MWUCX5?%+X;7KZGX<N+N[MEY^V:0[!\?]-(NOZ,*XW4KT/C7,NZW/:CALOQ^M
M&7LI_P`K^'Y/^O0^R*,`5\?:+^T7X^TH_9]6AL=96,[6\^(P2CZE<#/U6N^T
M[]J'1'51JOA6_MF[FVF28?KM-7#'T);NWJ85N'\=3>D>9>37_#GT)17C4/[2
M'PYD4&1=6@/H]GG_`-!8U*W[1GPV`XGU-_863?U-;?6J/\R.)Y5C?^?,ON9[
M!17@]]^T[X2A4C3]!U:\/;S!'$/_`$(G]*XO6/VF_$MR'30_#UCIP/`DN)&G
M<?@-H_G6<L=0C]JYTTLBQ]3_`)=V]6D?518*I9B`!R2:\S\8_&[P3X2$EO'>
MC6M23C[)8L'P?1Y/NK^I]J^4/$?Q"\:^*PR:YXBNYX&/-O&WE0_]\)@'\<UR
MPVKA1@9X`%<%7,V]*:^\^APG"R3YL5._DO\`/_@'>>._BKXK\>R-!?W`LM*S
ME=.MB1&?3>>KGZ\>@K@R0HR2`!7?^%/A!X[\7,DEKI#Z?8MS]LOP8DQZJN-S
M?@,>]?1?@;X$>$O";Q7^I*=>U5/F$UR@\J(^J1\C/N<GZ5RPPU?$RYI?>SUJ
M^:8#+*?LJ5FU]F/ZO_/4\0^&WP1USQG)#JFM+-H^@$AM[+MFN1Z1J>@/]X_@
M#7UQH>A:3X<T:WT?1;*.RLK<82*,?F2>I)[D\FM(`#M2U[F'PT*"]W?N?!9C
MFE?'SO4=HK9+9?\`!$I110*ZCR@Q1BEHH`3%&*6B@!,48I:*`$Q1BEHH`3%&
M*6B@#FO$'@+PAXJ!.O\`A^RO9"/]<T>V4?1UPWZUY?J_[,OA"[8OH^L:EI;'
MG:S+.@_!@#^M>ZT5A/#TJGQ1.[#YABL/I2J-+M?3[MCY7O?V7_$,;-_9WBK3
MIU[>?`\9_0M68?V:/'@8@:GHI'KYTG_Q%?7=%<SR^@^GXGJQXCQZ5G)/Y(^1
M!^S1X\)P=3T4#_KM)_\`$5H6?[+_`(FD8?;_`!1ID"]_)ADD/Z[:^JZ*2RZ@
MNGXA+B/'M64DODCP72?V8O#%LP?6=?U'4<=4B"VZG\LG]:],\/?#;P1X7*R:
M+X<LX)U_Y>'3S9?^^WR1^%==1753P]*GK&)YE?,<7B-*M1M=KV7W+00`CO1B
3EHK<\\3%&*6B@!,4H&***`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
